ArticleVaccine2007
Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines.Frontiers in immunology · 2020Review
- Article
- Biomedical applications of glycosylphosphatidylinositol-anchored proteins.Journal of lipid research · 2016Review
- Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.Nanomedicine : nanotechnology, biology, and medicine · 2015Article
- Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.Biotechnology and bioengineering · 2015Article
- Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination.Journal of virology · 2014Article
- Article
- Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells.PloS one · 2012Article
- Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles.Virology journal · 2011Article
- Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model.PloS one · 2011Article
- Article
- Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid.Virology · 2010Article
- Host responses from innate to adaptive immunity after vaccination: molecular and cellular events.Molecules and cells · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Extensive glycosylation and variable loops of the HIV envelope protein (Env) are reported to shield some neutralizing epitopes. Here, we investigated the immunogenicity of mutated HIV Envs presented in virus-like particles (VLPs). We immunized mice with simian human immunodeficiency virus (SHIV) VLPs containing mutant HIV Env with reduced glycosylation (3G), variable loop-deleted mutations (dV1V2), or combinations of both types of mutations (3G-dV2-1G), and evaluated immune responses. Immune sera from mice that received VLPs with modified HIV Envs (3G or dV1V2) showed higher neutralizing activities against the homologous HIV 89.6 virus as well as heterologous viruses when compared with wild type SHIV VLP-immunized mice. Lymphocytes from immunized mice produced HIV Env-specific cytokines, with the 3G-dV2-1G mutant producing high levels of cytokines. Interestingly, both dendritic cells and B cells were found to interact with VLPs suggesting that VLPs are effective immunogens. Therefore, this study suggests that VLPs containing modified HIV Env have the potential to be developed as candidate vaccines capable of inducing cellular and humoral immune responses including neutralizing activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.